Biotechnology
HiRO Leads Cross‑Border Dialogue at JPM, Offering Insights for Biotechs Seeking Asian Investment
SOMERSET, N.J., March 3, 2026 /PRNewswire/ -- Harvest Integrated Research Organization (HiRO), a global contract research organization specializing in strategic planning for clinical development and cross‑border clinical trial solutions and services, concluded a successful presence at the 44th An...
2026-03-03 22:30
1837
Insilico Medicine and Liquid AI Announce Strategic Partnership Delivering Lightweight Scientific Foundation Models for Drug Discovery
Single 2.6B-parameter model achieves state-of-the-art performance across drug discovery benchmarks while running entirely on private pharmaceutical infrastructure CAMBRIDGE, Mass., March 3, 2026 /PRNewswire/ -- Insilico Medicine and Liquid AI today announced a partnership that creates lightweigh...
2026-03-03 22:25
2706
REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for hum...
2026-03-03 22:00
1278
Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
TAIPEI and SAN DIEGO, March 3, 2026 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a clinical stage company focusing on development of first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced the signing of a major strategic Memorandum of Understa...
2026-03-03 15:51
2272
Efor strengthens its presence in Asia with the acquisition of No deviation
LYON, France, March 3, 2026 /PRNewswire/ -- Efor, a global leader specializing in quality and compliance for the Life Sciences industry, announces the acquisition of Singapore-based No deviation, a company recognized for its expertise in Commissioning, Qualification & Validation (CQV), Computer S...
2026-03-03 09:00
1824
US BioTek Laboratories Completes Merger With NutriPATH Pathology
SEATTLE and MELBOURNE, Australia, March 3, 2026 /PRNewswire/ -- US BioTek Laboratories, a leading functional laboratory specializing in advanced immunological and integrative diagnostics, today announced the completion of its merger with NutriPATH Pathology, a respected functional pathology labo...
2026-03-03 02:15
2123
Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
Australia's Therapeutic Goods Administration (TGA), responsible for approval of the safety, quality, and efficacy of therapeutic goods, has determined that Skyhawk's SKY-0515 orally-administered small molecule therapy for the treatment of Huntington's disease meets TGA eligibility criteria for re...
2026-03-03 01:20
2717
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Xolair®
PHILADELPHIA, March 2, 2026 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio"), a clinical-stage biotech company focused on discovery and development of biologics targeting allergic and autoimmune diseases, proudly announced positive topline results from a Phase II clinical trial of it...
2026-03-02 22:00
1710
ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease. SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare an...
2026-03-02 22:00
1853
Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
LEHI, Utah, March 2, 2026 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing therapies grounded in human biology, today announced that it will deliver a company presentation at the BIO Investment & Growth Summit. David Bearss, Ph.D., Chief Executive Officer ...
2026-03-02 21:35
1500
Shangpu Group Issues Market Position Statement Recognizing SALIAI's Patented Cellular Essence Global Pioneer
BEIJING and GUANGZHOU, China, March 2, 2026 /PRNewswire/ -- SALIAI ("Guangzhou SALIAI Stem Cell Science and Technology Co., Ltd." and "Guangzhou SALIAI Biological Gene Engineering Co., Ltd.," collectively referred to as "SALIAI") is a China-based biotechnology company engaged in stem cell researc...
2026-03-02 16:14
1848
WuXi Biologics Included in S&P Global Sustainability Yearbook for Fourth Consecutive Year
SHANGHAI, March 1, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced it has been included in the S&P Global Sustainability Yearbook 2026 ("Yearbook") in recognition of its strong performance in the 2025...
2026-03-02 11:21
1941
XPOVIO® Receives Reimbursement Approval in South Korea for a Second Multiple Myeloma Indication
- XPOVIO® is the first XPO1 inhibitor approved for reimbursement by South Korea's National Health Insurance Service (NHIS) for the treatment of adult patients with multiple myeloma (MM). - In South Korea, XPOVIO® has been approved for three indications across MM and diffuse large B-cell lymphoma...
2026-03-02 08:30
1573
Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
SAN FRANCISCO and SUZHOU, China, March 1, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabol...
2026-03-02 08:00
1468
Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis
SHANGHAI, HANGZHOU, China and BOSTON, March 2, 2026 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on therapies for immune and inflammatory diseases, today announced positive topline results from its Phase III ...
2026-03-02 08:00
1602
WuXi XDC Enters Strategic Collaboration with Earendil Labs on WuXiTecan-2 Payload-Linker Technology Platform
SHANGHAI, Feb. 27, 2026 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global CRDMO (Contract Research, Development, and Manufacturing Organization) specializing in antibody-drug conjugates (ADCs) and other bioconjugates, today announced a strategic collaboratio...
2026-02-27 17:11
3423
Earendil Labs Enters Strategic Collaboration with WuXi XDC on WuXiTecan-2 Payload-Linker Technology Platform
WILMINGTON, Del., Feb. 27, 2026 /PRNewswire/ -- Earendil Labs, a global leader in AI-driven research and development of next-generation biologics therapeutics, today announced a strategic collaboration with WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK) on WuXi XDC's proprietary WuXiTecan...
2026-02-27 15:00
2832
ImmVira's Oncolytic Product MVR-T3011 Expanded to BCG-Naïve Bladder Cancer Patients for the First Time with Clinical Data Presented at the 2026 ASCO GU Conference
SUZHOU, China, Feb. 26, 2026 /PRNewswire/ -- Intravesical BCG is the standard of care (SOC) for BCG-naïve high-risk non-muscle-invasive bladder cancer (NMIBC) patients. However, the scarcity of BCG products has become a global phenomenon, and coupled with the side effects of BCG therapy itself,me...
2026-02-27 08:00
3022
Illumina Launches TruPath Genome, Unveils NovaSeq X Roadmap, and Drives Cancer Breakthroughs with Connected Multiomics
* TruPath™ Genome offers more complete genome, with the simplest sample to sequencer workflow, and the new AGBT data demonstrates its accuracy in detecting rare genetic diseases * 40% increase in output to 35 billion reads, up to Q70 quality scores, improved turnaround time, and staggered sta...
2026-02-27 08:00
3032
Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
Highlights: * First participant enrolled and dosed with NUZ-001 in Regimen I of the HEALEY ALS Platform Trial evaluating NUZ-001 for the treatment of ALS * Approximately 160 participants with ALS will be enrolled in a 36-week randomised,double-blind, placebo-controlled adaptive Phase 2/3 clin...
2026-02-27 04:34
2877
Week's Top Stories
Most Reposted
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 310 media titles]
2026-02-26 09:30
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 308 media titles]
2026-02-26 19:57
SMU and Fudan Launch Region's First Tech-Focused DBA
[Picked up by 300 media titles]
2026-03-02 09:15Infobip is set to launch AgentOS to orchestrate autonomous AI-driven customer journeys at scale
[Picked up by 289 media titles]
2026-03-02 09:00
Klook's Spring Readiness Index shows how Asia's travelers are preparing for spring travel across Japan, South Korea, and Mainland China
[Picked up by 288 media titles]
2026-03-03 15:49
Most Read
COLUMBIA ASIA HOSPITAL BUKIT JALIL LAUNCHES NEW CATH LAB TO STRENGTHEN HEART CARE SERVICES
2026-03-02 14:24
8131
